about
Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazoleCost-effectiveness of highly active antiretroviral therapy in South Africa.Clinical characteristics and initial management of patients with tuberculous pericarditis in the HIV era: the Investigation of the Management of Pericarditis in Africa (IMPI Africa) registryEarly and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysisPharmacy refill adherence compared with CD4 count changes for monitoring HIV-infected adults on antiretroviral therapyComplications of antiretroviral therapy initiation in hospitalised patients with HIV-associated tuberculosisSystematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reactionDevelopment of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studiesTuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsThe epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.Tuberculosis in the tropics.Patient and provider delay in tuberculosis suspects from communities with a high HIV prevalence in South Africa: a cross-sectional studyHIV infection is associated with a lower incidence of constriction in presumed tuberculous pericarditis: a prospective observational studyMiliary tuberculosis: rapid diagnosis, hematologic abnormalities, and outcome in 109 treated adults.Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections.Early severe morbidity and resource utilization in South African adults on antiretroviral therapy.Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study.Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.Improving the evidence base of Markov models used to estimate the costs of scaling up antiretroviral programmes in resource-limited settingsHemostatic Changes Associated With Increased Mortality Rates in Hospitalized Patients With HIV-Associated Tuberculosis: A Prospective Cohort StudyPerformance of serum C-reactive protein as a screening test for smear-negative tuberculosis in an ambulatory high HIV prevalence populationFactors influencing retention in care after starting antiretroviral therapy in a rural South African programme.Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy.Lack of association between stavudine exposure and lipoatrophy, dysglycaemia, hyperlactataemia and hypertriglyceridaemia: a prospective cross sectional studyThe development of simple anthropometric measures to diagnose antiretroviral therapy-associated lipodystrophy in resource limited settingsBaseline predictors of sputum culture conversion in pulmonary tuberculosis: importance of cavities, smoking, time to detection and W-Beijing genotypeRandomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndromeThe safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.The pharmacokinetics of nevirapine when given with isoniazid in South African HIV-infected individuals.Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimenIsoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trialKey toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.A novel Markov model projecting costs and outcomes of providing antiretroviral therapy to public patients in private practices versus public clinics in South Africa.HIV infection: epidemiology, pathogenesis, treatment, and prevention.Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study.Low lopinavir plasma or hair concentrations explain second-line protease inhibitor failures in a resource-limited settingCytotoxic mediators in paradoxical HIV-tuberculosis immune reconstitution inflammatory syndrome.Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets.
P50
Q24678763-36239E86-37E4-4492-884C-02097444BD98Q24814698-3F414F25-CF0D-44EA-91E3-4FD0ADDB6CBCQ25257355-81085FC3-2EA6-4EFC-B2BA-87691A951F0FQ28472043-C0C5F233-4EDF-4122-BCCA-5072B5E9F5FBQ28472810-A647D3A0-CD22-4B44-A620-6CB9B1968145Q28486096-02A5DBC3-DA12-422B-A032-3524A72C0795Q28533379-99A6CAA5-3A0D-4550-926D-3878781DCC5AQ28743478-E9D4A1A0-BFAF-4CDC-9E5B-EF15A006209CQ28749315-CE634311-66C6-4BC7-8E4A-CC590A589E3FQ30235074-9F39D4BE-AB5A-4E2E-96F2-888316388960Q30330528-60D92033-D72C-46B1-8C50-6DA25FBB1697Q33337508-3E9415A5-FFE2-4ED2-BAC3-AD8B616E1C9FQ33340254-0460BDE2-F94D-4A50-B86E-7D690F6E566AQ33409643-7D4E0A4B-97AB-4152-B729-0E2DEA3CEC79Q33416170-23758356-3FE7-4B9B-B48C-DB3CC1F4D8EEQ33518021-FEE7BF57-648E-4DE4-A4FF-A7E37B524ADFQ33547682-9B4E0F77-2A76-44B8-8D5D-DC337F0D4873Q33592530-F2885E03-CC0E-4CAD-9214-EBC70317D421Q33605816-DBB8061F-57AF-4DF4-91B2-8724F126B5D3Q33623045-C9EC5BFB-E1E6-4BE9-81D7-F463BD61A4A4Q33712746-46CEACD4-FA2D-47C9-B2BE-34D7798058F5Q33798016-37CD4F96-299C-478D-85C9-1D10D16C4FABQ33894714-11267CD0-35D8-4441-BAE6-64AA0E1128E4Q33925552-7E98052B-1A1E-4A13-BEA8-254D8AD3953AQ34039225-95ADFF66-2F6E-4429-9D95-B19AE524AE49Q34067682-D623250A-B240-477F-8F8E-F059A1775D9BQ34125133-C4041E09-2728-4794-97E1-53DBB80C142FQ34130659-F3ADF25B-FCF4-459B-BFF4-F4EE8EF113F8Q34193050-FDAD0EDC-9F57-459D-85AA-E4DBF97E9CC6Q34251459-9F1CF65A-1C5E-48A6-B60D-DC31246DCF63Q34251506-21F26CB4-5E7A-4FFE-BAD1-A0597ED279CCQ34498914-2E3989CE-510B-472D-89A4-3B171D783BD8Q34519039-4760B42A-1015-46E3-A87C-32C3F9C02D09Q34536677-90A41A5B-973A-465B-AFE8-02BFF62C8FB7Q34583843-976FD1AD-A8FA-4D14-B8D8-C27F82E38399Q34662270-DA74DDF7-194A-46D8-824E-8F7AC49D14BEQ34706948-5D8F2628-EF3E-4EE9-A296-EB26FDE3EDA4Q34778123-D735DFF1-231E-486A-B131-EEF4E7CAFF18Q35056457-7908C81D-A154-4A77-A964-0C07F72CF07BQ35065871-1CE2C2FD-F95D-4930-AA0B-5BA3A706F9E6
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Gary Maartens
@ast
Gary Maartens
@en
Gary Maartens
@es
Gary Maartens
@nl
Gary Maartens
@sl
type
label
Gary Maartens
@ast
Gary Maartens
@en
Gary Maartens
@es
Gary Maartens
@nl
Gary Maartens
@sl
prefLabel
Gary Maartens
@ast
Gary Maartens
@en
Gary Maartens
@es
Gary Maartens
@nl
Gary Maartens
@sl
P1053
F-3836-2014
P106
P1153
16157672200
P21
P31
P3829
P496
0000-0003-3080-6606